Socioeconomic Disparities in Multiple Myeloma Survival in New South Wales Australia: A Population-Based Cohort Study
Treatment access gaps explain most survival gaps in multiple myeloma by socioeconomic status, pointing toward fixable policy targets.
This population-based cohort of 6,030 MM patients in Australia confirms significant socioeconomic survival disparities, with low-SES patients having 27% higher excess mortality risk than high-SES patients. Treatment access (ASCT, hospital type) mediates most of this disparity, pointing to urgent need for equitable treatment access policies.
What the study was
- Study design
- Retrospective population-based cohort study (cancer registry)
- Population
- Adults diagnosed with multiple myeloma 2008-2019 in New South Wales, Australia
- Sample size
- 6030
- Category
- Public Health
- Maturity
- Validated
- Journal
- Cancer Control
Why it surfaced
Large registry cohort (n=6,030) quantifying MM survival disparities by SES in Australia; actionable findings on treatment access barriers.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.